Alan Dunton joins EpiCept as non-executive chair
This article was originally published in Scrip
EpiCept Corporation, focused on the development and commercialisation of treatments for cancer and pain, has appointed Dr Alan Dunton to its board of directors as non-executive chair. Dr Dunton replaces Bob Savage, who will remain on the board as a director. Dr Dunton is the founder of Danerius, a consulting company that advises pharma and biotech companies on issues related to drug development. He is also a director at Targacept, Palatin Technologies and Oragenics. He previously served as president and CEO of Panacos Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.